Ganymed Pharmaceuticals Ag

Johannes Gutenberg-Universität Mainz

Astellas Pharma Gmbh

Biontech Ag

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Biontech Cell & Gene Therapies Gmbh

Tron-translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz

Ganymed Pharmaceuticals Gmbh

Biontech Se

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

UniversitÄtsmedizin Der Johannes Gutenberg-Universitat Mainz

Johannes Gutenberg Universität

Other

Ludwig Institute for Cancer Research Limited

Tron—translationale Onkologie An Der Universitat

Ozlem Tureci

Ugur Sahin

Lloyd J Old

Michael Koslowski

Stefan Stevanovic

Yao-tseng Chen

Stefan Woll

Stefan Jacobs

Michael Erdeljan

Bernd Hubner

Jens Schumacher

Tana Omokoko

Christiane Regina Stadler

Cornelia Heinz

Michael Weichel

Gerd Helftenbein

Petra Simon

Gunda Brandenburg

Thorsten Klamp

Magdalena Jadwiga Utsch

Michael Pfreundschuh

Ali O Gure

Rita Mitnacht-Kraus

Korden Walter

Maria Kreuzberg

Dirk Usener

Sebastian Kreiter

Harald-Gerhard Geppert

Thomas Michael Hiller

Cornelia Adriana Maria Heinz

Sylvia Luxen

Daniel Maurus

Stefan Fritz

Fabrice Le Gall

Philippe Thiel

Holger Hoff

Silke Holtkamp

Meike Wagner

Torsten Seppmann

Sabine Hacker

Markus Fiedler

Tim Beissert

Christoph Uherek

Phillippe Thiel

Karolina Anna Mroz

Sandra Schneider

Petra Oehm

Arne Jendretzki

Andrea Breitkreuz

Lisa Hebich

Laura Plum

Julia Holland

Rita Mitnachtkraus

Stephan Fritz

Ugar Sahin

Cristoph Uherek

Georg Rammensee

It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

Modification of RNA, producing an increased transcript stability and translation efficiency

The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.

Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer

The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

Antibodies against claudin 18.2 useful in cancer diagnosis

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Antibodies for treatment of cancer expressing claudin 6

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.

Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma

The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

Diagnosis and therapy of cancer involving cancer stem cells

The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Claudin-18.2-specific immunoreceptors and T cell epitopes

The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Drug conjugates comprising antibodies against claudin 18.2

The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.

Antigen-specific T cell receptors and T cell epitopes

The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

Recombinant vaccines and use thereof

Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer

Growing community of inventors

Mainz, Germany

Ozlem Tureci